Navigation Links
Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
Date:4/23/2008

armaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA immunotherapeutics for cancer, in which the expressed protein is an immune system stimulant; DNA vaccines for infectious diseases, in which the expressed protein is an immunogen; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and serve significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue development of Allovectin-7(R); whether Vical will be able to recruit patients into the AIMM trial as planned, if at all; whether the results from the Phase 2 trial or those reflected in the video report are indicative of results in any future testing of Allovectin-7(R); whether Vical will receive all of the clinical trial funding from AnGes under the collaborative agreement, which will depend on continued development of Allovectin-7(R) and certain other conditions, as well as AnGes' compliance with its contractual obligations under the agreement; whether Vical or others will evaluate potential additional applications of the company's technology; whether Allovectin-7(R) or any other product candidates will be shown to be saf
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015 Research ... the addition of the "Wound Care ... Opportunities: 2015-2020 Analysis And Forecasts" report ... information and evaluation of the global Wound ... manufacturers, segmentation, product offerings, competitive shares, financial ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
(Date:7/27/2015)... -- Syneron Medical Ltd. (NASDAQ: ... in the aesthetic medical device marketplace, announced today that ... Safety (MFDS) regulatory clearance for the PicoWay® picosecond laser. ... orders from its Korean distribution partner, with additional commercial ... quarter 2015. Amit Meridor, Chief Executive Officer ...
Breaking Medicine Technology:Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4
... HORSHAM, Pa. , Jan. 14 Findings ... and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) in the ... The New England Journal of Medicine.  The results ... STELARA than with etanercept over a 12-week period.  The first-of-its-kind ...
... , OSHKOSH, Wis. ... ImproMed, Inc. creators of the Infinity veterinary practice ... services on behalf of veterinarians, announce the integration of VetCentric,s ... the release of v4.5 of Infinity, veterinarians can offer home ...
Cached Medicine Technology:STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 3STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 4STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 5STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 6STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 7STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 8STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 9VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 2VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 3
(Date:7/27/2015)... ... July 28, 2015 , ... Almost a year ago, the US ... counseling for persons who are obese and those who are overweight with at least ... mandate will affect any commercial health plan with a program year start after August ...
(Date:7/27/2015)... ... July 27, 2015 , ... Specific cardiovascular risk factors, ... brain volumes that may be early indicators of Alzheimer’s disease and dementia, according ... that vascular risk factors damage the brain and can result in cognitive impairment,” ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National ... a 2015 Professional Woman of the Year. Ms. Baum-Lappe is recognized with this ... professional women in the country, spanning virtually every industry and profession, the National ...
(Date:7/27/2015)... ... July 27, 2015 , ... The FSH Society ... incurable disease, facioscapulohumeral muscular dystrophy (FSHD), today announced the introduction of the first-ever ... care guideline is published today. , This new guideline condenses the results ...
(Date:7/27/2015)... ... July 27, 2015 , ... Eugene Batelli, D.P.M., F.A.C.F.A.S, just recently ... “The patient is high-end athlete, whose accomplishments include running in 27 triathlons and swimming ... pain, which was diagnosed as tendinitis. I did an ultrasound and found a ...
Breaking Medicine News(10 mins):Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 3Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3Health News:NAPW Inducts Gilda Baum-Lappe, Journalist / Correspondent of Hollywood Foreign Press Association Into its VIP Woman of the Year Circle 2Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3
... AMDL, Inc. (NYSE Alternext US: ADL) , a ... its Chairman and CEO Mr. Douglas MacLellan has appeared ... 4, 2009 at 6:40 a.m. ET (3:40 a.m. PT). ... Fox Business News to discuss the Chinese business environment ...
... to Advance Understanding and Treatment of Pulmonary Fibrosis ... for Pulmonary Fibrosis (CPF) and the American Thoracic ... pulmonary, critical care and sleep physicians, today announced ... University Medical Center (Columbus, OH) and Harikrishna ...
... to share their heart-healthy lifestyle choicesDALLAS, Feb. 4 ... while others are life changing. Heart disease is the ... research shows that eighty percent of cardiac events in ... choices for their hearts, involving diet, exercise and abstinence ...
... Invisicare to ChinaLAS VEGAS and PLAINSBORO, N.J., Feb. 4 ... the developers of Invisicare , a ... for topical products, and RHEI Pharmaceuticals NV, a Belgium ... China, today announced they have signed a first option ...
... (Nasdaq: CADX ), a biopharmaceutical company focused ... for use in the hospital setting, announced today that ... the company,s corporate overview on Tuesday, February 10, 2009 ... BIO CEO and Investor Conference at the Waldorf Astoria ...
... Several big names in professional football and television ... 28 for the Third Annual National Walk for Epilepsy. ... Alan Faneca, and Atlanta Falcons running back Jason Snelling, ... their own teams of friends, relatives and fans. Together ...
Cached Medicine News:Health News:AMDL Inc.'s Chairman & CEO Mr. Douglas MacLellan Featured on FOX Business News Wednesday, February 4, 2009 2Health News:AMDL Inc.'s Chairman & CEO Mr. Douglas MacLellan Featured on FOX Business News Wednesday, February 4, 2009 3Health News:Coalition for Pulmonary Fibrosis and American Thoracic Society Announce Recipients of 2009-10 Research Awards 2Health News:Coalition for Pulmonary Fibrosis and American Thoracic Society Announce Recipients of 2009-10 Research Awards 3Health News:Coalition for Pulmonary Fibrosis and American Thoracic Society Announce Recipients of 2009-10 Research Awards 4Health News:Go Red For Women(R) Hosts Casting Call to Beat No. 1 Killer of Women With Celebrity Supporter Andie MacDowell 2Health News:Go Red For Women(R) Hosts Casting Call to Beat No. 1 Killer of Women With Celebrity Supporter Andie MacDowell 3Health News:Go Red For Women(R) Hosts Casting Call to Beat No. 1 Killer of Women With Celebrity Supporter Andie MacDowell 4Health News:Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals 2Health News:Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals 3Health News:Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals 4Health News:Video: Celebrities and Professional Athletes Invite the Public to Join them at the Third Annual National Walk for Epilepsy on March 28, in Washington, D.C. 2Health News:Video: Celebrities and Professional Athletes Invite the Public to Join them at the Third Annual National Walk for Epilepsy on March 28, in Washington, D.C. 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: